Literature DB >> 17621554

Investigation on the agonistic and antagonistic biological activities of synthetic Chlamydia lipid A and its use in in vitro enzymatic assays.

Holger Heine1, Sabine Gronow, Alla Zamyatina, Paul Kosma, Helmut Brade.   

Abstract

The synthetic 1,4'-bisphosphorylated penta-acyl and tetra-acyl lipid A structures representing the major molecular species of natural chlamydial lipid A were tested for their endotoxic activities as measured by interleukin-8 release from human embryonic kidney (HEK) 293 cells expressing Toll-like receptor (TLR) 2 or TLR4. Both compounds were unable to activate HEK293 cells transiently transfected with TLR2. The penta-acyl lipid A was a weak activator of HEK293 cells expressing TLR4/MD-2/CD14 whereas tetra-acyl lipid A was inactive even at high concentrations. The weak activity of the penta-acyl lipid A could be antagonized by the tetra-acyl derivative of Escherichia coli lipid A (compound 406) or the anti-CD14 monoclonal antibody MEM-18. Both, tetra- and pentaacyl lipid A were unable to antagonize the activity of synthetic E. coli-type lipid A (compound 506) or smooth lipopolysaccharide of Salmonella enterica serovar Friedenau. Tetra- and penta-acyl lipid A served as acceptors for Kdo transferases from E. coli, Chlamydia trachomatis and Chlamydophila psittaci as shown by in vitro assays and detection of the products by thin layer chromatography and immune staining with monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17621554     DOI: 10.1177/0968051907079122

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  8 in total

1.  Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis.

Authors:  Jiangwei Yao; Yasser M Abdelrahman; Rosanna M Robertson; John V Cox; Robert J Belland; Stephen W White; Charles O Rock
Journal:  J Biol Chem       Date:  2014-06-23       Impact factor: 5.157

2.  Lipooligosaccharide is required for the generation of infectious elementary bodies in Chlamydia trachomatis.

Authors:  Bidong D Nguyen; Doreen Cunningham; Xiaofei Liang; Xin Chen; Eric J Toone; Christian R H Raetz; Pei Zhou; Raphael H Valdivia
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

Review 3.  Sensing the enemy, containing the threat: cell-autonomous immunity to Chlamydia trachomatis.

Authors:  Ryan Finethy; Jörn Coers
Journal:  FEMS Microbiol Rev       Date:  2016-11-01       Impact factor: 16.408

Review 4.  Therapeutic Targets in Chlamydial Fatty Acid and Phospholipid Synthesis.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Front Microbiol       Date:  2018-09-25       Impact factor: 5.640

5.  Chlamydia trachomatis Lipopolysaccharide Evades the Canonical and Noncanonical Inflammatory Pathways To Subvert Innate Immunity.

Authors:  Chunfu Yang; Michael Briones; Janice Chiou; Lei Lei; Michael John Patton; Li Ma; Grant McClarty; Harlan D Caldwell
Journal:  mBio       Date:  2019-04-23       Impact factor: 7.867

6.  Effect of Sugars on Chlamydia trachomatis Infectivity.

Authors:  Giacomo Marziali; Antonella Marangoni; Claudio Foschi; Maria Carla Re; Natalia Calonghi
Journal:  Pathogens       Date:  2020-04-17

Review 7.  Lipopolysaccharide Recognition in the Crossroads of TLR4 and Caspase-4/11 Mediated Inflammatory Pathways.

Authors:  Alla Zamyatina; Holger Heine
Journal:  Front Immunol       Date:  2020-11-27       Impact factor: 7.561

8.  The intestinal archaea Methanosphaera stadtmanae and Methanobrevibacter smithii activate human dendritic cells.

Authors:  Corinna Bang; Katrin Weidenbach; Thomas Gutsmann; Holger Heine; Ruth A Schmitz
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.